<mets:mets xmlns:mets="http://www.loc.gov/METS/" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.loc.gov/METS/ https://www.loc.gov/standards/mets/mets.xsd" OBJID="oai:wwu.de:10270236-7872-4548-a6c9-40059271ba93" LABEL="University of Muenster, Institutional Repository MIAMI"  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
          <mets:metsHdr CREATEDATE="2022-11-09T15:03:11">
            <mets:agent TYPE="OTHER" ROLE="OTHER" OTHERTYPE="SOFTWARE">
              <mets:name>Memory Alpha</mets:name>
            </mets:agent>
          </mets:metsHdr>
          <mets:dmdSec ID="DMD_10270236-7872-4548-a6c9-40059271ba93">
            <mets:mdWrap MIMETYPE="text/xml" MDTYPE="MODS">
              <mets:xmlData>
                <mods:mods xmlns:mods="http://www.loc.gov/mods/v3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-7.xsd" version="3.7">
                  <mods:titleInfo type="uniform" lang="eng">
                    <mods:title script="Latn">The role of KCNQ-channels in the pathophysiology of multiple sclerosis</mods:title>
                  </mods:titleInfo>
                  <mods:name type="personal" valueURI="http://d-nb.info/gnd/1228907773">
                    <mods:namePart type="given">Anna-Katharina</mods:namePart>
                    <mods:namePart type="family">Delank</mods:namePart>
                    <mods:namePart type="date">1995-</mods:namePart>
                    <mods:displayForm>Delank, Anna-Katharina</mods:displayForm>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">aut</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="personal" valueURI="http://d-nb.info/gnd/124795161" altRepGroup="1">
                    <mods:namePart type="given">Sven</mods:namePart>
                    <mods:namePart type="family">Meuth</mods:namePart>
                    <mods:namePart type="date">1977-</mods:namePart>
                    <mods:displayForm>Meuth, Sven</mods:displayForm>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">ths</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="personal" valueURI="http://d-nb.info/gnd/124795161" altRepGroup="1">
                    <mods:namePart type="given">Sven G.</mods:namePart>
                    <mods:namePart type="family">Meuth</mods:namePart>
                    <mods:namePart type="date">1977-</mods:namePart>
                    <mods:displayForm>Meuth, Sven G.</mods:displayForm>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">ths</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>Universitäts- und Landesbibliothek Münster</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>ULB Münster</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>Landesbibliothek Münster / Universitäts- und Landesbibliothek Münster</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>Universität Münster / Universitäts- und Landesbibliothek</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:genre>doctoralThesis</mods:genre>
                  <mods:genre authority="dct">Text</mods:genre>
                  <mods:originInfo>
                    <mods:dateIssued keyDate="yes">2020</mods:dateIssued>
                    <mods:dateOther>2020-12-04</mods:dateOther>
                    <mods:issuance>monographic</mods:issuance>
                  </mods:originInfo>
                  <mods:originInfo>
                    <mods:dateIssued encoding="w3cdtf">2021-03-11</mods:dateIssued>
                    <mods:dateModified encoding="w3cdtf">2021-03-11</mods:dateModified>
                    <mods:edition>[Electronic ed.]</mods:edition>
                  </mods:originInfo>
                  <mods:language>
                    <mods:languageTerm type="code" authority="iso639-2b">eng</mods:languageTerm>
                  </mods:language>
                  <mods:physicalDescription>
                    <mods:form>electronic</mods:form>
                    <mods:reformattingQuality>access</mods:reformattingQuality>
                    <mods:internetMediaType>application/pdf</mods:internetMediaType>
                    <mods:digitalOrigin>born digital</mods:digitalOrigin>
                  </mods:physicalDescription>
                  <mods:abstract lang="ger">Multiple Sklerose geht mit Veränderungen der neuronalen Reizweiterleitung und Ionenkanal-Expression einher. Betroffen sind u.a. KCNQ-Kanäle, spannungsabhängige Kalium Kanäle, die die neuronale Aktivität regulieren. Das Antikonvulsivum Retigabine öffnet KCNQ-Kanäle und setzt somit die neuronale Erregbarkeit herab. Eine prophylaktische Retigabine Therapie erzielte eine Verbesserung des Outcomes einer experimentellen autoimmunen Enzephalitis, einem MS-Tiermodell. Mit Hilfe des Cuprizone-Modells untersuchten wir den Einfluss der Kanäle auf Neurodegeneration und zeigten, dass mit Retigabine behandelte Mäuse unter weniger Auffälligkeiten in Verhaltensexperimenten litten. Dies weist auf ein besseres Lern- und Erinnerungsvermögen der Tiere hin, welches durch die neurodegenerativen Vorgänge stark beeinflusst sein kann. Daher ergeben sich Hinweise auf eine neuroprotektive Eigenschaft von Retigabine und konsekutiv auf einen Einfluss von KCNQ-Kanälen in der Pathophysiologie von MS.</mods:abstract>
                  <mods:tableOfContents lang="eng">1. Introduction .............................................................................................................. 1&#13;
1.1 Multiple Sclerosis ................................................................................................... 1&#13;
1.2 Pathophysiology of MS .......................................................................................... 2&#13;
1.3 Animal Models in MS Research ............................................................................. 4&#13;
1.3.1 Experimental Autoimmune Encephalitis ............................................................. 5&#13;
1.3.2 Cuprizone Model of De- and Remyelination ....................................................... 6&#13;
1.3.3 Behavior Experiments in Animal Models of MS .................................................. 7&#13;
1.3.3.1 Behavioral Correlates of EAE Mice .............................................................. 9&#13;
1.3.3.2 Behavioral Correlates of Cuprizone Mice ..................................................... 9&#13;
1.4 Neuronal KCNQ-Channels ................................................................................... 10&#13;
1.4.1 Excitability Changes of Neurons Observable in MS and its Animal Models ..... 10&#13;
1.4.2 The Role of Ion Channels in the Pathophysiology of MS .................................. 11&#13;
1.4.3 KCNQ-channels ................................................................................................ 12&#13;
1.5 Aim of this Thesis ................................................................................................. 14&#13;
2. Materials ................................................................................................................ 14&#13;
2.1 Instruments .......................................................................................................... 14&#13;
2.2 Expendable Material and Reagents ..................................................................... 15&#13;
2.3 Media and Buffers ................................................................................................ 15&#13;
2.4 Antibodies and Primer .......................................................................................... 16&#13;
2.5 Software ............................................................................................................... 16&#13;
3. Methods ................................................................................................................. 17&#13;
3.1 Animals and Experimental Design ....................................................................... 17&#13;
3.1.1 Experimental Autoimmune Encephalitis (EAE) ............................................. 17&#13;
3.1.2 Cuprizone Diet ............................................................................................... 18&#13;
3.2 Behavior Experiments .......................................................................................... 19&#13;
3.2.1 Elevated Plus Maze (EPM) ........................................................................... 19&#13;
3.2.2 Open Field Test (OF) .................................................................................... 20&#13;
3.2.3 Novel Object Recognition (NOR) .................................................................. 20&#13;
3.2.4 Auditory Pavlovian Conditioning .................................................................... 21&#13;
3.3 In Vitro Experiments ............................................................................................. 21&#13;
3.3.1 Isolation of Splenocytes ................................................................................ 21&#13;
3.3.2 Isolation of Lymphocytes ............................................................................... 22&#13;
3.3.3 Retigabine Titration ....................................................................................... 22&#13;
3.3.4 Proliferation Assay ........................................................................................ 23&#13;
3.3.5 Cytokine Quantification ................................................................................. 24&#13;
3.3.6 mRNA Isolation and cDNA Synthesis ........................................................... 25&#13;
3.3.7 PCR KCNQ ................................................................................................... 26&#13;
3.3.8 Gel Electrophoresis ....................................................................................... 27&#13;
3.3.9 Real-Time PCR (RT-PCR) ............................................................................ 27&#13;
3.4 Statistics ............................................................................................................... 28&#13;
4. Results ................................................................................................................... 29&#13;
4.1 The Effect of KCNQ-Channels on Experimental Autoimmune Encephalitis ........ 29&#13;
4.2 Novel Object Recognition of EAE Mice treated with Retigabine .......................... 30&#13;
4.3 Expression Pattern of KCNQ-Channels in Different Organs ................................ 32&#13;
4.4 Retigabine Titration .............................................................................................. 34&#13;
4.5 The Effect of Retigabine Administration on Splenocyte Proliferation ................... 36&#13;
4.6 The Effect of Retigabine on Cytokine Production ................................................ 37&#13;
4.7 The Effect of XE991 Administration on Splenocyte Proliferation ......................... 39&#13;
4.8 Expression Pattern of KCNQ-Channels in CNS Resident Cells .......................... 40&#13;
4.9 Open Field Test of Cuprizone Mice treated with Retigabine ................................ 41&#13;
4.10 Elevated Plus Maze of Cuprizone Mice treated with Retigabine ....................... 44&#13;
4.11 Open Field Test of Cuprizone Mice treated with XE991 .................................... 47&#13;
4.12 Elevated Plus Maze of Cuprizone Mice treated with XE991 .............................. 50&#13;
4.13 The Effect of a Pharmacological Treatment of KCNQ-Channel on the Novel&#13;
Object Recognition Test performed with Cuprizone Mice .......................................... 53&#13;
4.14 Different Learning Abilities of Cuprizone Mice under the Influence of Retigabine&#13;
or XE991 Treatment tested in an Auditory Pavlovian Conditioning Paradigm ........... 56&#13;
5. Discussion .............................................................................................................. 60&#13;
5.1 Summary of the results ........................................................................................ 60&#13;
5.2 Interpretation of the Main Findings ...................................................................... 60&#13;
5.2.1 Retigabine Treatment Ameliorates the Course of EAE ................................. 60&#13;
5.2.2 KCNQ-channels are not Involved in Inflammation ........................................ 61&#13;
5.2.3 Retigabine Treatment Influences Neurodegenerative Processes in Cuprizone&#13;
Animal Experiments ............................................................................................... 62&#13;
5.3 Limitations and Critique of Methodology .............................................................. 63&#13;
6. Conclusions and Perspectives: .............................................................................. 64&#13;
7. Bibliography ........................................................................................................... 66&#13;
8. List of Figures ........................................................................................................ 77&#13;
9. List of Abbreviations ............................................................................................... 79&#13;
10. Lebenslauf ........................................................................................................... 83&#13;
11. Danksagung ......................................................................................................... 85&#13;
12. Anhang .................................................................................................................... I&#13;
Table 1: Instruments ..................................................................................................... I&#13;
Table 2: Expandable Material and Reagents ............................................................... II&#13;
Table 3: Antibodies and Primer .................................................................................. VI&#13;
Table 4: Software ...................................................................................................... VII&#13;
Table 6: cytokine detection beats ............................................................................. VII&#13;
Table 7: TaqMan Primers ........................................................................................ VIII</mods:tableOfContents>
                  <mods:targetAudience>specialized</mods:targetAudience>
                  <mods:subject>
                    <mods:topic lang="ger">Multiple Sclerose; KCNQ-Kanäle; Neurodegeneration; Cuprizone; EAE; Retigabine</mods:topic>
                  </mods:subject>
                  <mods:classification authority="ddc">610</mods:classification>
                  <mods:identifier type="urn">urn:nbn:de:hbz:6-28039498680</mods:identifier>
                  <mods:location>
                    <mods:url access="object in context">https://miami.uni-muenster.de/Record/10270236-7872-4548-a6c9-40059271ba93</mods:url>
                  </mods:location>
                  <mods:accessCondition type="use and reproduction">
                    <mods:extension>
                      <ma:maWrap xmlns:ma="http://memoryalpha.ulb.uni-muenster.de">
                        <ma:licence>
                          <ma:displayLabel>CC BY 4.0</ma:displayLabel>
                          <ma:targetUrl>http://creativecommons.org/licenses/by/4.0/</ma:targetUrl>
                        </ma:licence>
                      </ma:maWrap>
                    </mods:extension>
                  </mods:accessCondition>
                  <mods:recordInfo>
                    <mods:recordIdentifier>oai:wwu.de:10270236-7872-4548-a6c9-40059271ba93</mods:recordIdentifier>
                  </mods:recordInfo>
                </mods:mods>
              </mets:xmlData>
            </mets:mdWrap>
          </mets:dmdSec>
          <mets:amdSec ID="AMD_10270236-7872-4548-a6c9-40059271ba93">
            <mets:rightsMD ID="RIGHTSMD_10270236-7872-4548-a6c9-40059271ba93">
              <mets:mdWrap MDTYPE="OTHER" MIMETYPE="text/xml" OTHERMDTYPE="DVRIGHTS">
                <mets:xmlData>
                  <dv:rights xmlns:dv="http://dfg-viewer.de/">
                    <dv:owner>Universitäts- und Landesbibliothek Münster</dv:owner>
                  </dv:rights>
                </mets:xmlData>
              </mets:mdWrap>
            </mets:rightsMD>
            <mets:digiprovMD ID="DIGIPROVMD_10270236-7872-4548-a6c9-40059271ba93">
              <mets:mdWrap MDTYPE="OTHER" MIMETYPE="text/xml" OTHERMDTYPE="DVLINKS">
                <mets:xmlData>
                  <dv:links xmlns:dv="http://dfg-viewer.de/">
                    <dv:reference>https://miami.uni-muenster.de/Record/10270236-7872-4548-a6c9-40059271ba93</dv:reference>
                    <dv:presentation/>
                  </dv:links>
                </mets:xmlData>
              </mets:mdWrap>
            </mets:digiprovMD>
          </mets:amdSec>
          <mets:fileSec>
            <mets:fileGrp USE="DEFAULT">
              <mets:file MIMETYPE="application/pdf" CHECKSUM="30148a2a1db58cf6bb5135e49ffd08810999b5eabe1f4fc900d0dfebb128b3f4" CREATED="2021-03-11T13:55:31" CHECKSUMTYPE="SHA-256" SIZE="8934746" ID="ID_FIL_diss_delank.pdf_DEFAULT">
                <mets:FLocat xlink:href="https://repositorium.uni-muenster.de/document/miami/10270236-7872-4548-a6c9-40059271ba93/diss_delank.pdf" LOCTYPE="URL"/>
              </mets:file>
            </mets:fileGrp>
            <mets:fileGrp USE="DOWNLOAD">
              <mets:file MIMETYPE="application/pdf" ID="DOW10270236-7872-4548-a6c9-40059271ba93">
                <mets:FLocat xlink:href="https://repositorium.uni-muenster.de/transfer/miami/10270236-7872-4548-a6c9-40059271ba93" LOCTYPE="URL"/>
              </mets:file>
            </mets:fileGrp>
          </mets:fileSec>
          <mets:structMap TYPE="PHYSICAL">
            <mets:div ID="ID_PHY_10270236-7872-4548-a6c9-40059271ba93" TYPE="physSequence">
              <mets:div ID="ID_PHY_diss_delank.pdf">
                <mets:fptr FILEID="ID_FIL_diss_delank.pdf_DEFAULT"/>
              </mets:div>
            </mets:div>
          </mets:structMap>
          <mets:structMap TYPE="LOGICAL">
            <mets:div ADMID="AMD_10270236-7872-4548-a6c9-40059271ba93" DMDID="DMD_10270236-7872-4548-a6c9-40059271ba93" ID="ID_LOG_10270236-7872-4548-a6c9-40059271ba93" TYPE="Monograph">
              <mets:div ID="ID_LOG_ID_PHY_diss_delank.pdf"/>
            </mets:div>
          </mets:structMap>
          <mets:structLink>
            <mets:smLink xlink:from="ID_LOG_10270236-7872-4548-a6c9-40059271ba93" xlink:to="ID_PHY_10270236-7872-4548-a6c9-40059271ba93"/>
            <mets:smLink xlink:from="ID_LOG_ID_PHY_diss_delank.pdf" xlink:to="ID_PHY_diss_delank.pdf"/>
          </mets:structLink>
        </mets:mets>